Kelvin A. Baggett, MD, has been appointed managing director of Patient Square Capital's newly established EMPIRIC Institute.
The EMPIRIC Institute — which stands for excellence in medicine, patient impact research, innovation and care — was formed to measure and research patient impact within Patient Square Capital's portfolio companies, according to a July 27 news release.
Dr. Baggett will lead the institute as managing director, in addition to serving as chair and head of patient impact. He also serves on the Baltimore-based Johns Hopkins Bloomberg School of Public Health's advisory board and as a board member for the Prostate Cancer Foundation.